LIVINGSTON, NJ / ACCESSWIRE / March 30, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2019.
Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, commented, 'We have made significant strides in 2019 in order to commercialize our CompuFlo® Epidural System in 2020. During the year, we successfully trialed our CompuFlo® Epidural System in multiple hospitals and medical schools-placing the system with key opinion leaders, continuing important clinical studies and working with anesthesiologists in the U.S. and Europe. We also completed and published nine clinical studies, which further validated the CompuFlo® Epidural System's ability to safely and effectively identify the epidural space. Our unique, computer-controlled, real-time pressure-sensing technology provides anesthesiologists an objective and quantifiable technique to build confidence and success.'
'We have begun speaking with Group Purchasing Organizations (GPO) in order to obtain approval of the CompuFlo® Epidural System within their facilities. The GPOs represent a sizable opportunity since some of these groups have hundreds of hospitals within their network. Once we get an approval, it should shorten the sales cycle and open us up to larger markets. Our studies thus far have shown significant reductions in epidural punctures and complication rates by using the CompuFlo® Epidural System. Studies have shown that our technology not only benefits patients but also should lower the cost associated with treating complications such as dural punctures.'
'Turning to our dental business, we saw a decrease in sales, which was largely related to a decrease in sales to China. However, in the U.S., our exclusive distribution agreement with Henry Schein continues to pay off as the sales have been consistent throughout the year. Due to the current Covid-19 pandemic and the reduced hours and closings of dental offices throughout the country and the rest of the world, we anticipate that our revenue for the second quarter, and possibly the third quarter, may be affected. However, at this point in time it is too early to determine an estimate of what the second or third quarter impact will be, or the effect Covid-19 may have on our fourth quarter revenue.'
'We continue to evolve and innovate our technology. In the beginning of 2020, we announced that we received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent on the CompuWave technology, which is being integrated into the CompuFlo® Epidural System. This advanced and breakthrough technology provides further verification of epidural placement and real-time notification of obstruction or displacement of a catheter. This patent provides IP protection around the CompuFlo instrument for another 20 years, which further enhances our position at the forefront of the computerized injection market. We remain encouraged by the outlook for our company and look forward to providing further updates as they unfold.'
For the years ended December 31, 2019 and 2018, revenues were approximately $8.4 million and $9.6 million, respectively. Gross profit for the year ended December 31, 2019 was $5.7 million or 68% of revenue versus $4.4 million or 46% of revenue for the year ended December 31, 2018. During 2018, the Company recorded a reserve of approximately $1.2 million for the underlying inventory associated with deferred cost due to Milestone China's market under performance and liquidity constraints. Operating loss for the year ended December 31, 2019 was approximately $(3.9) million versus approximately $(7.9) million for the year ended December 31, 2018. Operating loss for 2018 included a $1.5 million impairment of long-lived assets related to non-core patents. In 2019, the Company incurred a non-cash expense of approximately $3.65 million due to the shares and warrants issued in the public and private offerings as well as other issuance of common stock during 2019 for which the Company did not have a sufficient number of authorized shares of common stock to cover the exercise and issuance of approximately 5,850,000 outstanding equity instruments. After the impact of the derivative liability, the net loss was approximately $(7.5) million, or $(0.16) per share for the year ended December 31, 2019, versus net loss of $(7.4) million, or $(0.21) per share, for the comparable period in 2018.
Milestone Scientific's executive management team will host a conference call at 8:30 AM Eastern Time on Tuesday, March 31, 2020 to discuss the Company's financial results for the full year ending December 31, 2019, as well as the Company's corporate progress and other developments.
The conference call will be available on the Company's website at www.milestonescientific.com, or via telephone by dialing toll free 877-407-0778 for U.S. callers, or +1 201-689-8565 for international callers. A webcast will also be archived on the Company's website and a telephone replay of the call will be available approximately one hour following the call, through Tuesday, April 14, 2020, and can be accessed by dialing 877-481-4010 for U.S. callers, or +1 919-882-2331 for international callers and entering the pass code 33928.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
MILESTONE SCIENTIFIC AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MILESTONE SCIENTIFIC AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2019 AND 2018
David Waldman or Natalya Rudman
Crescendo Communications, LLC
SOURCE: Milestone Scientific Inc.
View source version on accesswire.com: